Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT

Blood (2022) 140 (Supplement 1): 1346–1349.

https://doi.org/10.1182/blood-2022-168521

Published: 2022

Journal Articles

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Blood (2022) 140 (Supplement 1): 10185–10188.

https://doi.org/10.1182/blood-2022-162336

Published: 2022

Journal Articles

CTPS1 Is a Novel Therapeutic Target in Multiple Myeloma That Synergizes with Inhibition of ATR, CHEK1 or WEE1

Christina Pfeiffer, Alexander Michael Grandits, Hélène Asnagli, Anja Schneller, Julia Huber, Niklas Zojer, Martin Schreder, Andrew Parker, Arnold Bolomsky, Philip Beer, Heinz Ludwig

Blood (2022) 140 (Supplement 1): 7088–7089.

https://doi.org/10.1182/blood-2022-160333

Published: 2022

Journal Articles

Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

Blood (2021) 138 (Supplement 1): 1669.

https://doi.org/10.1182/blood-2021-150311

Published: 2021

Journal Articles

Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-140918

Published: 2020

Journal Articles

Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Blood (2020) 136 (Supplement 1): 27–29.

https://doi.org/10.1182/blood-2020-140701

Published: 2020

Journal Articles

Patterns of Renal Recovery and Toxicity with Novel Agent-Based Induction Triplets in Newly Diagnosed Multiple Myeloma - an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group

Blood (2019) 134 (Supplement_1): 1840.

https://doi.org/10.1182/blood-2019-125235

Published: 2019

Journal Articles

Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma — AGMT_MM1

Heinz Ludwig, MD, Wolfram Pönisch, MD, Stefan Knop, Martin Schreder, MD, Daniel Lechner, MD, Roman Hajek, MD PhD, Eberhard Gunsilius, MD, Karl Jochen Krenosz, MD, Andreas Petzer, MD, Katja Weisel, MD, Hermann Einsele, MD PhD, Richard Greil, MD, Niklas Zojer, MD

Blood (2018) 132 (Supplement 1): 3275.

https://doi.org/10.1182/blood-2018-99-118061

Published: 2018

Journal Articles

Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM

Blood (2018) 132 (Supplement 1): 598.

https://doi.org/10.1182/blood-2018-99-116663

Published: 2018

Journal Articles

Lenalidomide, Adriamycin and Dexamethasone (RAD) Versus Bortezomib, Lenalidomide and Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) - Post-Induction Response and MRD Results By Flow Cytometry and NGS from a Phase 3 Randomized Controlled Clinical Trial (RCT)

Blood (2018) 132 (Supplement 1): 1979.

https://doi.org/10.1182/blood-2018-99-116067

Published: 2018

Journal Articles

SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7 + normal lymphocytes

Tea Gogishvili, Sophia Danhof, Sabrina Prommersberger, Julian Rydzek, Martin Schreder, Christian Brede, Hermann Einsele, Michael Hudecek

Blood (2017) 130 (26): 2838–2847.

https://doi.org/10.1182/blood-2017-04-778423

Published: 2017

Includes: Supplemental data

Journal Articles

Upregulation of CD38 Expression on Multiple Myeloma Cells By the HDAC Inhibitor Ricolinostat Augments the Efficacy of Daratumumab

Estefania Garcia-Guerrero, Sophia Danhof, Martin Schreder, MD, José A. Pérez-Simón, Hermann Einsele, Michael Hudecek

Blood (2017) 130 (Supplement 1): 1803.

https://doi.org/10.1182/blood.V130.Suppl_1.1803.1803

Published: 2017

Journal Articles

A Whole Blood Gene Expression Signature Accurately Diagnoses Multiple Myeloma and Differentiates Patients in Remission from Those with Active and Progressive Disease

Martin Schreder, MD, Santiago Barrio Garcia, PhD, Ignat Drozdov, Ken Herrmann, MDPhD, Hermann Einsele, Mark Kidd, PhDDABCC, Irvin M Modlin, MDPhDDSc, K. Martin Kortüm, MD

Blood (2017) 130 (Supplement 1): 4344.

https://doi.org/10.1182/blood.V130.Suppl_1.4344.4344

Published: 2017

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance

Heinz Ludwig, MD, Wolfram Pönisch, MD, Alexander Egle, MD, Stefan Knop, MD, Martin Schreder, MD, Daniel Lechner, MD, Roman Hajek, Eberhard Gunsilius, Michael A. Fridrik, MD, Andreas Petzer, MD, Katja C. Weisel, Dietger Niederwieser, MD, Axel Hinke, PhD, Richard Greil, MD, Niklas Zojer, MD

Blood (2017) 130 (Supplement 1): 1857.

https://doi.org/10.1182/blood.V130.Suppl_1.1857.1857

Published: 2017

Journal Articles

Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab

Estefanía García-Guerrero, Tea Gogishvili, Sophia Danhof, Martin Schreder, Celine Pallaud, Jose Antonio Pérez-Simón, Hermann Einsele, Michael Hudecek

Blood (2017) 129 (25): 3386–3388.

https://doi.org/10.1182/blood-2017-03-770776

Published: 2017

Includes: Supplemental data

Journal Articles

Parallel Evolution of Multiple PSMB5 mutations in a Myeloma Patient Treated with Bortezomib

Santiago Barrio, PhD, Thorsten Stühmer, PhD, Eva Teufel, Clara Barrio-Garcia, Manik Chatterjee, MD, Martin Schreder, MD, Mithun Das Gupta, MD, Andreas Rosenwald, MD, Raoul Tibes, MD PhD, Esteban Braggio, PhD, A. Keith Stewart, MD, Ralf C Bargou, MD, Hermann Einsele, MD, K Martin Kortüm, MD

Blood (2016) 128 (22): 3282.

https://doi.org/10.1182/blood.V128.22.3282.3282

Published: 2016

Journal Articles

Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial

Heinz Ludwig, MD, Eberhard Gunsilius, MD, Michael Fridrik, MD, Richard Greil, Andreas Petzer, MD, Thomas Kühr, Univ. Doz. Dr., Stefan Knop, MD, Martin Schreder, MD, Elisabeth Rauch, Mag., Wolfram Poenisch, MD, Niklas Zojer, MD

Blood (2016) 128 (22): 3335.

https://doi.org/10.1182/blood.V128.22.3335.3335

Published: 2016

Journal Articles

Boost of Immune Responses Against NY-ESO-1 Following Local Radiation Therapy in Patients with Multiple Myeloma: A Potential Contribution to Tumor Immunosurveillance

Miriam Alb, PhD, Jörg Tamihardja, MD, Erdwine Klinker, MD, Martin Schreder, MD, Stefan Knop, MD, Hermann Einsele, MD, Thomas Hünig, PhD, Andreas Rosenwald, MD, Michael Flentje, MD, Stephan Mielke, MD

Blood (2016) 128 (22): 4512.

https://doi.org/10.1182/blood.V128.22.4512.4512

Published: 2016

Journal Articles

Panobinostat Induces Upregulation of CD38 and Augments the Anti-Myeloma Efficacy of Daratumumab in Pre-Clinical Models

Estefania Garcia-Guerrero, Tea Gogishvili, PhD, Sophia Danhof, MD, Martin Schreder, MD, Celine Pallaud, PhD, Thomas Lehmann, PhD, Hermann Einsele, MD, Michael Hudecek, MD

Blood (2016) 128 (22): 4481.

https://doi.org/10.1182/blood.V128.22.4481.4481

Published: 2016

Journal Articles

CAR-Engineered T Cells Specific for the Elotuzumab Target SLAMF7 Eliminate Primary Myeloma Cells and Confer Selective Fratricide of SLAMF7+ Normal Lymphocyte Subsets

Sophia Danhof, MD, Tea Gogishvili, PhD, Silvia Koch, Martin Schreder, MD, Stefan Knop, Hermann Einsele, Michael Hudecek, MD

Blood (2015) 126 (23): 115.

https://doi.org/10.1182/blood.V126.23.115.115

Published: 2015

NARROW

Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

CTPS1 Is a Novel Therapeutic Target in Multiple Myeloma That Synergizes with Inhibition of ATR, CHEK1 or WEE1

Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)

Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Patterns of Renal Recovery and Toxicity with Novel Agent-Based Induction Triplets in Newly Diagnosed Multiple Myeloma - an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group

Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma — AGMT_MM1

Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM

Lenalidomide, Adriamycin and Dexamethasone (RAD) Versus Bortezomib, Lenalidomide and Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) - Post-Induction Response and MRD Results By Flow Cytometry and NGS from a Phase 3 Randomized Controlled Clinical Trial (RCT)

SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7 + normal lymphocytes

Upregulation of CD38 Expression on Multiple Myeloma Cells By the HDAC Inhibitor Ricolinostat Augments the Efficacy of Daratumumab

A Whole Blood Gene Expression Signature Accurately Diagnoses Multiple Myeloma and Differentiates Patients in Remission from Those with Active and Progressive Disease

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance

Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab

Parallel Evolution of Multiple PSMB5 mutations in a Myeloma Patient Treated with Bortezomib

Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial

Boost of Immune Responses Against NY-ESO-1 Following Local Radiation Therapy in Patients with Multiple Myeloma: A Potential Contribution to Tumor Immunosurveillance

Panobinostat Induces Upregulation of CD38 and Augments the Anti-Myeloma Efficacy of Daratumumab in Pre-Clinical Models

CAR-Engineered T Cells Specific for the Elotuzumab Target SLAMF7 Eliminate Primary Myeloma Cells and Confer Selective Fratricide of SLAMF7+ Normal Lymphocyte Subsets

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only